Post by
Bearbull17 on Mar 06, 2018 9:44am
Celgene Finalizes Acquisition of Juno Therapeutics
Celgene Finalizes Acquisition of Juno Therapeutics 06 Mar 2018 08:43 ET 08:43 AM EST, 03/06/2018 (MT Newswires) -- Celgene (CELG), a biotech company, said early Tuesday it completed its $9 billion acquisition of Juno Therapeutics. As a result, the common stock of Juno will no longer be listed for trading on the NASDAQ Global Select Market. With the acquisition, Celgene gains full global rights to JCAR017 (lisocabtagene maraleucel; liso-cel), a CD-19 targeted CAR T therapy currently in pivotal trials for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Celgene said it expects the addition of JCAR017 and other cellular immunotherapy products in Juno's pipeline to accelerate revenue diversification with meaningful growth drivers from 2020 and beyond. "Our colleagues at Juno are developing some of the most promising approaches to treating cancer, and we are excited to add their pioneering work to Celgene's leading hematology and oncology research and commercial platform," said Mark Alles, CEO of Celgene.